Head-to-head · WeighScore
Get Thin MD vs Maves
The verdict
Maves takes it — 71.6/100 to 66.7/100.
Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Get Thin MD | Maves |
|---|---|---|
| WeighScore | 66.7/100 | 71.6/100 |
| Grade | C | C |
| Scorecard rank | #185 | #91 |
| Semaglutide | $199/mo (compounded) | $99/mo (starting dose, first-month rate, compounded) |
| Tirzepatide | $299/mo (compounded) | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #185 · C
Strengths
- 3-month compounded semaglutide at $169/mo is among the lowest ongoing prices in the category
- Price-lock promise — same price every dose, no hidden fees
- Both compounded and brand-name options on one platform (sema, tirz, plus Ozempic and Zepbound)
- Nationwide availability with async evaluation — no in-person visit
- Broader wellness menu (sermorelin, NAD+, HRT, hair loss) lets you consolidate protocols
Where it loses points
- Compounded medications aren't FDA-approved and lack the review of brand-name GLP-1s
- Pharmacy partners not named — no way to verify the compounding source or batch testing
- Claims nationwide coverage but publishes no state list — confirm at intake
- Headline results (9.6 lbs in 30 days) come from self-reported patient data, not a trial
- Wide wellness funnel may steer you toward non-weight-loss protocols
Graded #91 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
- All 50 states covered, stated explicitly
- Both brand (Maves) and parent (Homera Health) disclosed for accountability
Where it loses points
- 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- Tirzepatide pricing not stated on the homepage — only listed as an offering
- Named medical director / clinical leadership not disclosed
- Refund and cancellation policy not detailed publicly
- Corporate address and arbitration venue not disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.